Abstracts

Modification of PARP Inhibitor Use in mCRPC With Co-Occurring BRCA1/2 Mutations and MSI-High Status

Updating the Value Pathways powered by NCCN Prostate Cancer Pathway to remove PARP inhibitors for patients with co-occurring BRCA1/2 mutations and MSI-H status led to a significant decrease in PARPi use and increased adoption of pembrolizumab. This shift reflects improved clinical alignment with emerging evidence that monoallelic BRCA1/2 mutations in MSI-H tumors do not confer PARPi sensitivity, highlighting the value of integrating genomic insights into pathway-driven care.

Decision Support Documentation for Targeted Therapy Eligibility in Breast Cancer

This study found that re-prompting providers within the Clear Value Plus clinical decision support tool significantly improved biomarker documentation and increased use of precision therapies for breast cancer. The intervention enhanced identification of actionable AKT1, PTEN, and PIK3CA alterations, supporting more consistent, guideline-aligned treatment decisions across the US Oncology Network.

From Approval to Action: Evaluating Review Timelines for Oncology Therapies in Value Pathways

This analysis found that the US Oncology Network’s Pathways Task Force reviewed most new FDA-approved and NCCN-endorsed oncology therapies within 60 days, demonstrating strong responsiveness to emerging evidence. The findings highlight an efficient, structured review process that maintains the relevance of Value Pathways in community oncology while balancing scientific rigor and timeliness.

Ensuring Access to Care: Using Tax-Exempt and Taxable Bond Funding for Consolidation of Outpatient Specialties

Radiation Business Solutions developed a novel nonprofit model to preserve independent community cancer centers by recapitalizing assets through bond market funding and uniting four Alaska centers under a single governance structure. This transition enhanced financial stability, expanded patient access, and fostered collaboration, demonstrating a sustainable framework for maintaining oncology services amid declining reimbursement and rising operational costs.

Streamlining Clinical Decision Support Through Integrated Education

The Launch N’ Learn feature enhances the Clear Value Plus clinical decision support tool by embedding direct, point-of-care links to guideline-based resources, reducing workflow disruptions and improving efficiency in oncology care. Early implementation across multiple cancer types showed strong provider engagement, particularly with complex staging tools, supporting its potential to improve evidence-based decision-making and Value Pathway adherence.

Green Light, Red Flags: A New Framework for Evaluating Oncology Accelerated Approvals

This study introduces the Clinical Benefit Index (CBI), a framework that integrates the ESMO Magnitude of Clinical Benefit Scale with real-world modifiers to assess the true clinical value of oncology therapies approved via the FDA’s Accelerated Approval pathway. Application of the CBI to biliary tract cancer treatments revealed that contextual factors—such as unmet need, trial design, and surrogate endpoint quality—can significantly alter a therapy’s assessed benefit, supporting more transparent and consistent value-based decisions.

Assessing EHR-to-EDC Data Transfer Solutions

The Flatiron Clinical Pipe EHR-to-EDC integration tool significantly streamlined clinical trial data management by automating the transfer of structured data, saving approximately 35 hours of manual entry across two oncology studies. The pilot demonstrated improved workflow efficiency and data accuracy, highlighting the potential for broader adoption and future expansion to include unstructured data elements for even greater research productivity.

Provision of Comparative Clinical Evidence to Support Pathway Decision-Making

The Value Pathways evidence tables, originally developed to aid therapy evaluations, have evolved into a widely accessed resource for US Oncology Network providers by integrating clinical trial data directly into electronic health records and the intranet. Usage has grown substantially—especially via the intranet—as expanded content including patient-reported outcomes and trial discontinuation rates has enhanced decision-making and workflow efficiency in oncology care.

Enhancing Oncology Documentation and Diagnosis Capture With Integrated AI Scribe in Electronic Health Record

Integration of the DeepScribe AI scribe into the OncoEMR system achieved high adoption across community oncology practices, improving documentation completeness and clinician experience without compromising workflow efficiency. AI-assisted encounters captured more comorbidities, social determinants of health, and detailed ICD-10 codes, suggesting that AI documentation tools can enhance data quality, reduce clinician burden, and support more sustainable oncology practice.

Cost-Effectiveness of BTKis in Medicare Patients With CLL in First-Line and Relapsed/Refractory Settings

This updated cost-effectiveness analysis found that ibrutinib, at its new Medicare maximum fair price (MFP), is more cost-effective than acalabrutinib and zanubrutinib at current wholesale acquisition costs for both first-line and relapsed/refractory CLL. With comparable clinical outcomes and substantially lower costs, ibrutinib was dominant in base-case analyses, indicating strong economic value from a US Medicare perspective.

Pharmacist-Driven Outcomes for Patients on Oral Oncology Medications: Clinical Impact of an Integrated Specialty Pharmacy Model

This evaluation found that integrated health system specialty pharmacy (HSSP) models significantly improve adherence and clinical outcomes for patients on oral oncology therapies through proactive pharmacist-led interventions. Pharmacist involvement enhanced medication safety, prevented complications, and maintained a 92% adherence rate, highlighting the model’s effectiveness in optimizing cancer care and reducing unplanned hospitalizations.

Efficacy, Safety, and End-of-Treatment Mutational Results From the 5-Year Follow-Up of the Phase 2 OPTIC Study in Patients With Chronic-Phase Chronic Myeloid Leukemia

The 5-year results of the phase 2 OPTIC trial confirm that response-based ponatinib dosing—starting at 45 mg daily and reducing to 15 mg upon achieving molecular response—maintains durable efficacy with manageable safety in patients with chronic-phase CML resistant to prior TKIs or harboring the T315I mutation. Long-term outcomes demonstrated sustained molecular responses, preserved survival, and lower mutation emergence, validating this dosing strategy’s optimal benefit-risk profile.

From Fragmented to Integrated: A Roadmap to Equity for Psychosocial Support in Rural and Underserved Cancer Programs

This analysis identified major structural, financial, and policy barriers limiting access to psychosocial oncology care, particularly in rural and underserved communities. A four-part implementation framework—focused on sustainability, team-based workforce development, integration into clinical workflows, and effective dissemination—was proposed to promote equitable, patient-centered cancer care through better mental health integration.

Session Coverage

Reinventing Health Care: Tom Koulopoulos on AI, Behavioral Shifts, and the Human Future of Medicine

Practical Insights for Embedding Whole-Person Care into Clinical Pathways

Policy and Payment Shifts on the Horizon: Navigating Uncertainty in Cancer Care

Scaling Bispecifics and CAR T-Cell Therapy in Community Oncology: From Promise to Practice

Theranostics: Clinical Promise, Operational Hurdles, and the Road Ahead

From Dispensing to Decision-Making: How Pharmacists Are Redefining Leadership in Oncology Care

How AI is Reshaping Clinical Practice, Governance, and Patient Trust

Reviewing a Decade of Oncology Pathways: Standardization, Gaps, and the Road to Real-Time Intelligence

Building a Transparent Framework for Predictable Cost of Care in Oncology Pathways

Real-World Evidence in Oncology: Opportunities, Challenges, and Clinical Impact

Panelist Interviews

Pharmacy-Driven Pathways: Enhancing Efficacy, Tolerability, and Value in Oncology Care

James Gilmore, PharmD, discusses how the American Oncology Network is elevating pharmacist-driven clinical pathways through data, technology, and collaboration to advance value-based care and enhance patient safety with innovative therapies like bispecific antibodies.

Evolving Pathways: How Stakeholder Collaboration is Shaping the PCC Model

Carole Tremonti, RN, MBA, discusses how the Predictable Cost of Care initiative evolved from expanding stakeholder engagement to advancing data transparency and real-world model testing, marking a pivotal shift toward truly data-driven clinical decision-making.

Defining the Future of Predictable Cost of Care: Insights from Phase 2

Gordon Kuntz discusses how the Predictable Cost of Care (PCC) Working Group is expanding its economic models to include patient-centric metrics by developing a parallel track that measures patient time, healthcare interactions, and variability in coverage, aiming to make the model more transparent, verifiable, and reflective of real patient impact.

Real-World Evidence in Action: Insights from CPC+CBEx 2025

Lalan Wilfong, MD, and Aimee Ginsburg Chesnick, PharmD, BCPS, explore how real-world evidence is shaping drug approvals, clinical decision-making, and future opportunities for stronger, more actionable data.

CAR T-Cell Therapy and Bispecifics in the Community: Opportunities and Obstacles

Lavi Kwiatkowsky discusses how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap to expand patient access and streamline care.

 

Abstracts

Iris: Using a Telehealth Platform to Provide Virtual Supportive Care for Patients in Oncology

This case study illustrates how Iris by OncoHealth’s telehealth platform delivered comprehensive, virtual supportive care that improved symptom management, reduced emergency visits, and enhanced mental health support for a patient with metastatic colon cancer. By integrating multidisciplinary telehealth services—including nursing, psychosocial, and palliative support—Iris demonstrated the transformative potential of virtual care in improving access, continuity, and quality of oncology care.

Building an Episode of Care to Reduce Time to Treatment

Implementation of a structured lung nodule care pathway streamlined workflows, standardized follow-up processes, and significantly reduced time from suspicion to treatment. The initiative shortened diagnosis-to-treatment intervals by 44% for early-stage and 26% for late-stage cancers, improving care coordination, patient tracking, and timely initiation of therapy across the health system.

Impact of an EHR-Embedded Clinical Decision Support (CDS) Tool on Guideline Adoption: A Retrospective Analysis of Clinician Adaptation to Treatment Intensification in Prostate Cancer

This study found that oncology practices using the Flatiron Assist clinical decision support tool adopted updated NCCN Guideline–recommended combination regimens for metastatic prostate cancer much faster than non-users. After the guideline change, CDS-enabled sites reduced single-agent docetaxel use dramatically (from 90.9% to 27.6%), demonstrating that embedded decision support accelerates evidence-based treatment adoption and practice transformation.

Claims Payment Status for On-Pathway Navigations Across an Academic Cancer Center and its Network

This retrospective analysis at Dana-Farber Cancer Institute found that 99.7% of on-pathway treatment orders were ultimately paid by payers, demonstrating strong alignment between pathway-guided clinical decisions and payer approvals. The high concordance rate highlights the clinical validity of data-driven pathways and suggests opportunities to streamline prior authorization processes, reducing administrative delays in cancer care.

A Pilot Program of Automated Patient Identification for Survivorship Resources Using Clinical Oncology Pathways

This project developed an automated patient identification system that leverages clinical pathways data to efficiently recognize patients eligible for survivorship programs at Dana-Farber Cancer Institute. By integrating structured EHR and navigation data into a real-time dashboard, the system identified 272 eligible patients across melanoma, renal cell carcinoma, and testicular cancer, demonstrating a scalable model for improving survivorship outreach and care coordination.

Beyond the Diagnosis: Exploring the Multifaceted Distress Profile of Patients With Cancer

Analysis of over 269,000 distress screenings across seven US Oncology Network practices found that 43.5% of patients reported at least one health-related social need, with 11.6% experiencing clinically significant distress (score ≥4). Emotional concerns—especially anxiety, sadness, and depression—were strongly correlated with higher distress scores, emphasizing the need for integrated psychosocial and social support interventions to improve well-being and quality of life for patients with cancer.

Ready or Not: Assessment of Readiness for Oncology Value-Based Care Program Participation

This study demonstrated that readiness assessments effectively helped community oncology practices evaluate and prepare for participation in the Enhancing Oncology Model (EOM) value-based care program. Practices that completed the assessments showed substantial improvement in understanding requirements and operational readiness—rising from an average of 64% pre-launch to 89% after 90 days—highlighting the importance of structured preparation for successful VBC implementation.

The Economic Impact of Vial Sizes on Drug Waste of Bortezomib and Carfilzomib in Multiple Myeloma: The US Oncology Network Study

This study showed that drug waste and costs were substantially higher for bortezomib, which is available only in a single 3.5 mg vial, compared with carfilzomib, which offers multiple vial sizes. The introduction of a 10 mg carfilzomib vial in 2018 reduced waste by over 70% and saved $7.4 million, demonstrating that flexible vial sizing can significantly decrease financial loss and environmental impact in oncology care.

The Impact in Quality of Life of Adverse Events With Systemic Therapies for Metastatic Colorectal Cancer Previously Treated With Standard Therapies and Biologics in the United States

This study found that grade ≥3 adverse events in metastatic colorectal cancer significantly reduced patients’ quality of life—by more than twice the impact of disease progression. Among evaluated therapies, fruquintinib was associated with the smallest quality-of-life decrement from AEs compared with regorafenib, trifluridine/tipiracil (T/T), and T/T + bevacizumab, reinforcing its favorable tolerability and economic profile in previously treated patients with mCRC.

Clinical Benefits and Commonly Reported Adverse Events and Their Associated Costs in Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors in First-Line and Relapsed/Refractory Settings

This analysis found that ibrutinib, acalabrutinib, and zanubrutinib provide comparable clinical benefits and overall costs for both first-line and relapsed/refractory CLL. Adverse event–related costs were primarily driven by hematologic and infectious complications, and potential ibrutinib dose reductions further decreased AE costs, underscoring its maintained value and economic competitiveness among BTK inhibitors.

Session Coverage

CPC + CBEx 2024: CancerX Updates

CPC + CBEx 2024: Strategies for Patient Navigation Services

CPC + CBEx 2024: Managing Clinical & Financial Risk in Oncology

CPC + CBEx 2024: Pathways for Social Needs Assessment and Care

CPC + CBEx 2024: Integration of Medical Oncology and Surgical Specialties

CPC + CBEx 2024: Influence and Impact of Oncology Pathways

Panelist Interviews

Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care

James Hamrick, MD, MPH, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting value-based care to improve patient outcomes and cost-effectiveness.

Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships

John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.

Oncology Pathways Research: Challenges, Adoption, and Future Trends

Cindy Chen, shares insights into the challenges, adoption, and future trends of oncology pathways research. Her discussion draws on crucial points from her Clinical Pathways Congress + Cancer Care Business Exchange session with Lee Blansett.

Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams

Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality of life.

Understanding the Impact of Venture Capital and Private Equity in Oncology

Michael Kolodziej, MD, discusses the growing influence of venture capital and private equity in oncology care, highlighting the potential for these trends to reshape costs, partnerships, and innovation in the oncology landscape.

The Evolving Role of Pharmacists in Custom Pathway Implementation

Rebecca Maniago, PharmD, discusses the complexities of implementing custom clinical pathways, emphasizing the need for clear goals, robust resources, and ongoing updates, while highlighting the pivotal role of pharmacists in pathway development, regimen management, and enhancing patient outcomes.

Building Consensus for Predictable Cancer Care Costs: Applying the Delphi Method to Multidisciplinary Stakeholder Collaboration

Carole Tremonti, RN, MBA, discusses the critical role of clinical pathways in equitable cancer care, the application of the Delphi Method by the Predictable Cost of Care Working Group to foster multidisciplinary collaboration and transparency in decision-making, and the group’s focus on metastatic non-small cell lung cancer as an initial pilot for creating a cost-predictive model that balances stakeholder consensus.

Driving Innovation in Cancer Care: The Future of Value-Based Care in Oncology

Gordon Kuntz discusses the Delphi Method, a Predictable Cost of Care Model developed by the Predictable Cost of Care Working Group that enhances oncology market access strategies by standardizing and broadening the economic modeling of cancer treatment costs beyond just drug prices, while aiming to inform pathway developers, payers, and practices.

Session Coverage

New Dimensions in Comprehensive Genomic Testing

Treating the Individual: The Intersection of Personalized Medicine and Clinical Pathways

The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs

Pathway Use Beyond the Unidimensional Treatment Decision

Cancer Care at Home: Opportunities, Risks, and How to Prepare

Scaling Precision Medicine Expertise for Equitable Cancer Care: Breaking Barriers, Advancing Patient Outcomes

How Congress Plans to Address Patient and Hospital Challenges, and How This Could Affect Oncologists

The Impact of Health Care Industry Consolidation on Cancer Care and Partnerships

Using Clinical Pathways to Reduce Delays in Time to Treatment

How Clinical Pathways Can be Used For HER2-Positive Breast Cancer Therapies

CPC & CBEx 2023: Critical Trends in the Oncology Landscape

Panelist Interviews

AI in Health Care: Foundations, Myths, and Practical Applications

Ira Klein, MD, MBA, vice president of medical affairs for Tempus Labs, provides insight into the future of AI in health care and how it will help cut down on mundane tasks and increase oncologists’ efficiency.

How Patient-Centered Cancer Symptom Management Can Help Improve Patient Outcomes

David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, participated in a panel session titled "Treating the Individual." In this interview, Dr. Lobach provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.

Expanding Access to Care Through Academic-Community Cancer Care Collaboration

Harlan Levine, MD, president of health, innovation, and policy at City of Hope, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.  

Trends in the Rising Costs of Care Among Self-Insured Employers

Frederick M. Schnell, MD, FACP, National Cancer Treatment Alliance and Community Oncology Alliance, discusses the rising costs of cancer care for self-insured employers and how they can partner with cancer centers to continue to provide high-value care despite the cost increases.

Players and Disruptors in Health Care Industry Consolidation

Ronald Barkley, MS, JD, Cancer Center Business Development Group, provides an overview of the current consolidation of the health care industry and the major players and disruptors leading this transformation.

Updates from Washington Impacting Community Oncology Practices

Nicolas Ferreyros, managing director, Community Oncology Alliance spoke as part of the panel titled "Updates from Washington.” In this interview, he summarizes some of the latest developments from Washington that are impacting cancer care and providers in community oncology.

What the Growth of Medicare Advantage Means for Value-Based Care in Community Oncology

David Eagleton, Oncology Care Partners, shares his thoughts on the growth of Medicare Advantage and its impact on community oncology practices in providing value-based care.

How Technologies and New Models Are Changing Clinical Research

Sibel Blau, MD, medical director at Northwest Medical Specialties, and founding member and president/CEO of the Quality Cancer Care Alliance Network and Exigent Research, provides insights into the current state of clinical research in the oncology community and how technologies and new models are impacting this area.

The Future of Cancer Care At Home

Dan Nardi, CEO of Reimagine Care, discusses the future of cancer care in the home.

How Precision Medicine is Changing Cancer Care

Debyani Chakravarty, PhD, from Memorial Sloan Kettering Cancer Center, discusses her session on scaling precision medicine for equitable cancer care.

How Pathways Can Aid in Managing Patient Cost of Care

Chevon Rariy, MD, Oncology Care Partners, discusses how clinical pathways can help in providing personalized treatment to patients and managing patient cost of care. 

Reimagining Clinical Trials in the Community Setting

Ivy Altomare, MD, senior medical director at Flatiron Health, discusses the current state of clinical research in community oncology and how technologies and new models are changing clinical research. 

AI in Cancer Care: Separating Fact from Fiction

James Hamrick, MD, discusses his presentation at the 2023 Clinical Pathways Congress + Cancer Care Business Exchange meeting on how artificial intelligence is being used in oncology operations and care today and how it may impact the delivery of care, including clinical pathways, in the future.

 

Session Coverage

Cancer Care Equity and Collaboration

Value-Based Oncology Care Solutions for Self-Insured Employers

Optimizing Oncology Care in Older Adults

Quality of Care and Research Initiatives in the Enhancing Oncology Model

Pharmacy Benefits With Rising Costs of Cancer Care

System Challenges in Oncology Care—A Patient Perspective

Health Equity and Care Coordination From the Patient Perspective

Value-Based Care and COVID-19

Just in Time Clinical Trials: A Solution for Both Academia and Community Oncology

CancerLinQ Technology in the Oncology Community

ePROs Effect on Patient Health Outcomes

Precision Medicine and AI in Oncology Patient Care

Low-Value Care Directly Leads to Development of Cancer Genomic Pathways

Gene Sequencing in the Clinic

Complex Diagnostic Imaging and the CMS Imaging AUC Program

Integrating Social Determinants of Health

Using Real-Time Dynamics to Enhance Clinical Pathways

Decision Support Through Structured Data

Can Real-World Evidence Improve Clinical Pathways?

Optimal Utilization of Telehealth to Enhance Patient Care and Clinical Trial Participation

Panelist Interviews

Creating and Implementing Value-Based Pathways in Community Oncology

Sibel Blau, MD, Northwest Medical Specialties, summarizes her 2022 Oncology Clinical Pathways Congress presentation on creating and implementing value-based care pathways and the associated challenges in the health care system.

The Challenges and Evolution of Pathways in Urothelial Carcinoma

Daniel Vaena, MD, West Cancer Center and Research Institute, summarizes his 2022 Oncology Clinical Pathways Congress presentation that covers the evolution and unmet needs of the pathways in metastatic urothelial cancer, including subsequent lines of therapy and biomarker selection. 

Complexities in Current Cancer Care Systems and Strategies for Providing High-Level Patient Care

The complexities of cancer care have accelerated, creating challenges to providing consistent, high-level care for all patients. At the 2022 Oncology Clinical Pathways Congress, Lawrence Shulman, MD, Abramson Cancer Center at the University of Pennsylvania, discusses the need for having critical systems in place and unencumbered access to patient data to achieve optimal care, and emphasizes the role that coordinated clinical pathways can play in this process. 

Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment

Sayeh Lavasani, MD, MS, FRCPC, City of Hope National Cancer Center, gives an overview of her presentation on optimizing metastatic breast cancer care through clinical pathways. 

Value-Based Oncology Care Solutions for Self-Insured Employers

Margaret Rehayem, MA, National Alliance of Healthcare Purchaser Coalitions, takes the employer perspective on value-based care with technology advancements and how to help an employer look at the patient journey starting with prediagnosis all the way to returning to work.

Utilizing Pathways for Diagnosis, Treatment, and Survivorship in Cancer Care

Tatjana Kolevska, MD, Kaiser Permanente, presents at the 2022 Oncology Clinical Pathways Congress the importance of connecting all specialties in pathways, meaning screening, diagnosis, treatment, and survivorship, for consistent and up to date care.

The Role of Technology in Improving Oncology Pathways

Louis Culot, Philips Healthcare, discusses at the 2022 Oncology Clinical Pathways Congress how technology plays a central role in developing and improving clinical oncology pathways and also the barriers technology faces today.

Analyzing Pharmacy Benefits in Value-Based Oncology Pathways

James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways Congress.

Optimizing Clinical Trials in Academia and Community Oncology

Ira Klein, MD, Tempus Labs, discusses design in clinical trials, touching on current issues such as clinical workflow and operational processes, and the barriers to participating in a clinical trial in community oncology.

Telehealth Utilization in Clinical Trial Research and Participation

Matthew Lunning, DO, FACP, University of Nebraska Medical Center, discusses the expansion of telehealth during the “COVID era,” highlighting the importance of face-to-face encounters between patients and health care providers, and suggesting ways to successfully meet this demand in clinical trials utilizing telehealth.

Establishing Imaging Guidelines Within Oncology Pathways

Elliot Fishman, MD, Johns Hopkins Hospital, discusses imagining guidelines and the optimization of health care within oncology.

Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape

Janet Espirito, PharmD, Ontada, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.

CMS National Quality Strategy Focuses on Quality, Safety, Affordability Standards in Oncology Care

Lee Fleisher, MD, Chief Medical Officer for the Centers for Medicare and Medicaid Services (CMS), and Director of the Center for Clinical Standards and Quality at CMS, discusses the basis and goals of CMS’ National Quality Strategy.